Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

Ji Yan Liu, Yu Quan Wei, Li Yang, Xia Zhao, Ling Tian, Jian Mei Hou, Ting Niu, Fen Liu, Yu Jiang, Bing Hu, Yang Wu, Jing Mei Su, Yanyan Lou, Qiu Ming He, Yan Jun Wen, Jin Liang Yang, Bing Kan, Yong Qiu Mao, Feng Luo, Feng Peng

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The breaking of immune tolerance of "self-antigens" associated with angiogenesis is an attractive approach to cancer therapy by active immunity. We used vascular endothelial growth factor receptor-2 (VEGFR-2) as a model antigen to explore the feasibility of the immunotherapy with a vaccine based on a xenogeneic homologous protein. To test this concept, we prepared a quail homologous VEGFR-2 protein vaccine (qVEGFR) based on quail VEGFR-2. At the same time, a protein vaccine based on the corresponding ligand-binding domain of mouse self-VEGFR-2 (mVEGFR) was also prepared and used as a control. We found that immunotherapy with qVEGFR was effective at protective and therapeutic antitumor immunity in several solid and hematopoietic tumor models in mice. Autoantibodies against mouse VEGFR-2 (Flk-1) were identified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Anti-VEGFR antibody-producing B cells were detectable by ELISPOT. Endothelial deposition of immunoglobulins developed within tumor. VEGF-mediated endothelial cell proliferation was inhibited in vitro by immunoglobulins from qVEGFR-immunized mice. Antitumor activity was caused by the adoptive transfer of the purified immunoglobulins. Antitumor activity and production of autoantibodies against Flk-1 could be abrogated by the depletion of CD4+ T lymphocytes. Angiogenesis was apparently inhibited within the tumors, and the vascularization of alginate beads was also reduced. No marked toxicity was found in the immunized mice. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factor receptor associated with angiogenesis in a cross-reaction with single xenogeneic homologous protein.

Original languageEnglish (US)
Pages (from-to)1815-1823
Number of pages9
JournalBlood
Volume102
Issue number5
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Cancer Vaccines
Quail
Immunotherapy
Tumors
Vaccines
Immunoglobulins
Autoantibodies
Neoplasms
Proteins
Active Immunity
Enzyme-Linked Immunospot Assay
Antibody-Producing Cells
Immune Tolerance
Immunosorbents
T-cells
Growth Factor Receptors
Adoptive Transfer
Cross Reactions
Endothelial cells

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Liu, J. Y., Wei, Y. Q., Yang, L., Zhao, X., Tian, L., Hou, J. M., ... Peng, F. (2003). Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood, 102(5), 1815-1823. https://doi.org/10.1182/blood-2002-12-3772

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. / Liu, Ji Yan; Wei, Yu Quan; Yang, Li; Zhao, Xia; Tian, Ling; Hou, Jian Mei; Niu, Ting; Liu, Fen; Jiang, Yu; Hu, Bing; Wu, Yang; Su, Jing Mei; Lou, Yanyan; He, Qiu Ming; Wen, Yan Jun; Yang, Jin Liang; Kan, Bing; Mao, Yong Qiu; Luo, Feng; Peng, Feng.

In: Blood, Vol. 102, No. 5, 01.09.2003, p. 1815-1823.

Research output: Contribution to journalArticle

Liu, JY, Wei, YQ, Yang, L, Zhao, X, Tian, L, Hou, JM, Niu, T, Liu, F, Jiang, Y, Hu, B, Wu, Y, Su, JM, Lou, Y, He, QM, Wen, YJ, Yang, JL, Kan, B, Mao, YQ, Luo, F & Peng, F 2003, 'Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2', Blood, vol. 102, no. 5, pp. 1815-1823. https://doi.org/10.1182/blood-2002-12-3772
Liu, Ji Yan ; Wei, Yu Quan ; Yang, Li ; Zhao, Xia ; Tian, Ling ; Hou, Jian Mei ; Niu, Ting ; Liu, Fen ; Jiang, Yu ; Hu, Bing ; Wu, Yang ; Su, Jing Mei ; Lou, Yanyan ; He, Qiu Ming ; Wen, Yan Jun ; Yang, Jin Liang ; Kan, Bing ; Mao, Yong Qiu ; Luo, Feng ; Peng, Feng. / Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. In: Blood. 2003 ; Vol. 102, No. 5. pp. 1815-1823.
@article{4811b3db9d11454cbf6dd16906557cda,
title = "Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2",
abstract = "The breaking of immune tolerance of {"}self-antigens{"} associated with angiogenesis is an attractive approach to cancer therapy by active immunity. We used vascular endothelial growth factor receptor-2 (VEGFR-2) as a model antigen to explore the feasibility of the immunotherapy with a vaccine based on a xenogeneic homologous protein. To test this concept, we prepared a quail homologous VEGFR-2 protein vaccine (qVEGFR) based on quail VEGFR-2. At the same time, a protein vaccine based on the corresponding ligand-binding domain of mouse self-VEGFR-2 (mVEGFR) was also prepared and used as a control. We found that immunotherapy with qVEGFR was effective at protective and therapeutic antitumor immunity in several solid and hematopoietic tumor models in mice. Autoantibodies against mouse VEGFR-2 (Flk-1) were identified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Anti-VEGFR antibody-producing B cells were detectable by ELISPOT. Endothelial deposition of immunoglobulins developed within tumor. VEGF-mediated endothelial cell proliferation was inhibited in vitro by immunoglobulins from qVEGFR-immunized mice. Antitumor activity was caused by the adoptive transfer of the purified immunoglobulins. Antitumor activity and production of autoantibodies against Flk-1 could be abrogated by the depletion of CD4+ T lymphocytes. Angiogenesis was apparently inhibited within the tumors, and the vascularization of alginate beads was also reduced. No marked toxicity was found in the immunized mice. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factor receptor associated with angiogenesis in a cross-reaction with single xenogeneic homologous protein.",
author = "Liu, {Ji Yan} and Wei, {Yu Quan} and Li Yang and Xia Zhao and Ling Tian and Hou, {Jian Mei} and Ting Niu and Fen Liu and Yu Jiang and Bing Hu and Yang Wu and Su, {Jing Mei} and Yanyan Lou and He, {Qiu Ming} and Wen, {Yan Jun} and Yang, {Jin Liang} and Bing Kan and Mao, {Yong Qiu} and Feng Luo and Feng Peng",
year = "2003",
month = "9",
day = "1",
doi = "10.1182/blood-2002-12-3772",
language = "English (US)",
volume = "102",
pages = "1815--1823",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

AU - Liu, Ji Yan

AU - Wei, Yu Quan

AU - Yang, Li

AU - Zhao, Xia

AU - Tian, Ling

AU - Hou, Jian Mei

AU - Niu, Ting

AU - Liu, Fen

AU - Jiang, Yu

AU - Hu, Bing

AU - Wu, Yang

AU - Su, Jing Mei

AU - Lou, Yanyan

AU - He, Qiu Ming

AU - Wen, Yan Jun

AU - Yang, Jin Liang

AU - Kan, Bing

AU - Mao, Yong Qiu

AU - Luo, Feng

AU - Peng, Feng

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The breaking of immune tolerance of "self-antigens" associated with angiogenesis is an attractive approach to cancer therapy by active immunity. We used vascular endothelial growth factor receptor-2 (VEGFR-2) as a model antigen to explore the feasibility of the immunotherapy with a vaccine based on a xenogeneic homologous protein. To test this concept, we prepared a quail homologous VEGFR-2 protein vaccine (qVEGFR) based on quail VEGFR-2. At the same time, a protein vaccine based on the corresponding ligand-binding domain of mouse self-VEGFR-2 (mVEGFR) was also prepared and used as a control. We found that immunotherapy with qVEGFR was effective at protective and therapeutic antitumor immunity in several solid and hematopoietic tumor models in mice. Autoantibodies against mouse VEGFR-2 (Flk-1) were identified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Anti-VEGFR antibody-producing B cells were detectable by ELISPOT. Endothelial deposition of immunoglobulins developed within tumor. VEGF-mediated endothelial cell proliferation was inhibited in vitro by immunoglobulins from qVEGFR-immunized mice. Antitumor activity was caused by the adoptive transfer of the purified immunoglobulins. Antitumor activity and production of autoantibodies against Flk-1 could be abrogated by the depletion of CD4+ T lymphocytes. Angiogenesis was apparently inhibited within the tumors, and the vascularization of alginate beads was also reduced. No marked toxicity was found in the immunized mice. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factor receptor associated with angiogenesis in a cross-reaction with single xenogeneic homologous protein.

AB - The breaking of immune tolerance of "self-antigens" associated with angiogenesis is an attractive approach to cancer therapy by active immunity. We used vascular endothelial growth factor receptor-2 (VEGFR-2) as a model antigen to explore the feasibility of the immunotherapy with a vaccine based on a xenogeneic homologous protein. To test this concept, we prepared a quail homologous VEGFR-2 protein vaccine (qVEGFR) based on quail VEGFR-2. At the same time, a protein vaccine based on the corresponding ligand-binding domain of mouse self-VEGFR-2 (mVEGFR) was also prepared and used as a control. We found that immunotherapy with qVEGFR was effective at protective and therapeutic antitumor immunity in several solid and hematopoietic tumor models in mice. Autoantibodies against mouse VEGFR-2 (Flk-1) were identified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Anti-VEGFR antibody-producing B cells were detectable by ELISPOT. Endothelial deposition of immunoglobulins developed within tumor. VEGF-mediated endothelial cell proliferation was inhibited in vitro by immunoglobulins from qVEGFR-immunized mice. Antitumor activity was caused by the adoptive transfer of the purified immunoglobulins. Antitumor activity and production of autoantibodies against Flk-1 could be abrogated by the depletion of CD4+ T lymphocytes. Angiogenesis was apparently inhibited within the tumors, and the vascularization of alginate beads was also reduced. No marked toxicity was found in the immunized mice. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factor receptor associated with angiogenesis in a cross-reaction with single xenogeneic homologous protein.

UR - http://www.scopus.com/inward/record.url?scp=0041439704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041439704&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-12-3772

DO - 10.1182/blood-2002-12-3772

M3 - Article

VL - 102

SP - 1815

EP - 1823

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -